EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Next Generation CD44v6-Specific CAR-NK Cells Effective against Triple Negative Breast Cancer

Martin J Raftery, Alexander Sebastian Franzén iD, Clarissa Radecke, Abdelhadi Boulifa, Günther Schönrich iD, Sebastian Stintzing iD, Jens-Uwe Blohmer iD, Gabriele Pecher

International Journal of Molecular Sciences · 20.05.2023 · 24 (10) · 9038

DOI: 10.3390/ijms24109038 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 20.05.2023. Verfasst von Martin J Raftery und 7 weiteren Autor:innen. Beteiligte Einrichtung: Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: SPARK-program of the Berlin Institute of Health@Charite, Berlin Institute of Health at Charité.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is a medical need to develop new and effective therapies against triple-negative breast cancer (TNBC). Chimeric antigen receptor (CAR) natural killer (NK) cells are a promising alternative to CAR-T cell therapy for cancer. A search for a suitable target in TNBC identified CD44v6, an adhesion molecule expressed in lymphomas, leukemias and solid tumors that is implicated in tumorigenesis and metastases. We have developed a next-generation CAR targeting CD44v6 that incorporates IL-15 superagonist and checkpoint inhibitor molecules. We could show that CD44v6 CAR-NK cells demonstrated effective cytotoxicity against TNBC in 3D spheroid models. The IL-15 superagonist was specifically released upon recognition of CD44v6 on TNBC and contributed to the cytotoxic attack. PD1 ligands are upregulated in TNBC and contribute to the immunosuppressive tumor microenvironment (TME). Competitive inhibition of PD1 neutralized inhibition by PD1 ligands expressed on TNBC. In total, CD44v6 CAR-NK cells are resistant to TME immunosuppression and offer a new therapeutic option for the treatment of BC, including TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsReceptors, Chimeric AntigenHumansInterleukin-15LigandsCell Line, TumorKiller Cells, NaturalImmunotherapy, AdoptiveTumor Microenvironment

Stichwörter der Autor:innen

CARCAR-NKCD44v6TNBCcancerimmunotherapy

Substanzen

Interleukin-15LigandsReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany.
  • Onkologie und Tumorimmunologie, CCM, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Medizinische Klinik m. S. Hämatologie, Charitéplatz 1, 10117 Be…
  • Institute of Virology, CCM, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117 Berlin, Germany.
  • Department of Gynecology and Breast Cancer Center, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117 Berlin, Germany.

ORCID-Profile: Alexander Sebastian Franzén, Günther Schönrich, Sebastian Stintzing, Jens-Uwe Blohmer

Förderung

  • SPARK-program of the Berlin Institute of Health@Charite
  • Berlin Institute of Health at Charité

Zitieren

APA

Raftery, M. J., Franzén, A. S., Radecke, C., Boulifa, A., Schönrich, G., Stintzing, S., Blohmer, J. U., & Pecher, G. (2023). Next Generation CD44v6-Specific CAR-NK Cells Effective against Triple Negative Breast Cancer. International Journal of Molecular Sciences, 24(10), 9038. https://doi.org/10.3390/ijms24109038

Vancouver

Raftery MJ, Franzén AS, Radecke C, Boulifa A, Schönrich G, Stintzing S, et al. Next Generation CD44v6-Specific CAR-NK Cells Effective against Triple Negative Breast Cancer. International Journal of Molecular Sciences. 2023;24(10):9038. doi:10.3390/ijms24109038

BibTeX
@article{Raftery2023,
  author = {Raftery, Martin J and Franzén, Alexander Sebastian and Radecke, Clarissa and Boulifa, Abdelhadi and Schönrich, Günther and Stintzing, Sebastian and Blohmer, Jens-Uwe and Pecher, Gabriele},
  title = {Next Generation CD44v6-Specific CAR-NK Cells Effective against Triple Negative Breast Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {10},
  pages = {9038},
  doi = {10.3390/ijms24109038}
}
Kostenlos starten →